AN0025
Phase 1Small molecule
AN0025 is one of 44 small molecule programs targeting Esophageal Cancer. It is currently in Phase 1.
1
Indications
4
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
341 competitors in Esophageal Cancer
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Paraplatin
AAvyxa
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Camptosar
PfizerPhase 3
Taxotere
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Erbitux
IImclone
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Stivarga
BayerPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Advanced Solid Tumors2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AN0025. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAdlai Nortye Biopharma Co., Ltd.